share_log

Wedbush Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $15

Benzinga ·  Jun 21, 2023 08:46

Wedbush analyst Andreas Argyrides maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $17 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment